button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)

versus placebo
pembrolizumab alone vs. placebo 1 0.540.68

metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)

versus sunitinib
atezolizumab alone vs. sunitinib 1 1.19
atezolizumab plus bevacizumab vs. sunitinib 2 0.930.90
avelumab plus axitinib vs. sunitinib 1 0.800.69
nivolumab plus cabozantinib vs. sunitinib 1 0.600.51
nivolumab plus ipilimumab vs. sunitinib 3 0.680.98
pembrolizumab plus axitinib vs. sunitinib 1 0.530.69
pembrolizumab plus lenvatinib vs. sunitinib 1 0.660.39

mRCC - L1 - PDL1 negative metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 negative

versus sunitinib
atezolizumab plus bevacizumab vs. sunitinib 1 0.84

mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive

versus sunitinib
atezolizumab alone vs. sunitinib 1 1.03
atezolizumab plus bevacizumab vs. sunitinib 2 0.840.83
avelumab plus axitinib vs. sunitinib 1 0.690.61

metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)

versus everolimus
nivolumab alone vs. everolimus 1 0.730.88

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons